A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors

#2190

Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.

Aim(s): The aim of this prospective study was to compare the association between changes in plasma CgA and changes in tumor burden on CT in GEP-NET patients with residual disease.

Materials and methods: We included 239 patients with a CT followed by at least one additional CT between 1 and- 24 months later. Change in tumor size was defined and categorized by RECIST1.1. An event was defined as CgA measured within 6 weeks of a CT. In addition, in a post-hoc analysis an event was defined as a CgA measured 3-6 month prior to the CT. A 25% change in CgA discriminated between increased, unchanged or decreased plasma CgA levels. Patients were included in Denmark, Norway and Sweden from December 2010 to December 2013.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Dam G, Grønbæk H, Sørbye H, Thiis-Evensen E, Paulsson B,

Keywords: gep-net, ct, cga, correlation,